News Center

TOT BIOPHARM International Company Limited 東曜藥業股份有限公司


TOT BIOPHARM International Company Limited


Optimises Company Management Structure

to Promote Strategic Development Upgrade

*   *   *

Names Ms. Yeh-Huang, Chun-Ying

as Vice Chairman of the Board

Appoints Dr. Liu, Jun as Chief Executive Officer


(Hong Kong, 15 October 2020) TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK), is pleased to announce that Ms. Yeh-Huang, Chun-Ying, Executive Director, has been appointed as Vice Chairman of the Board while she has resigned as General Manager of the Company. Besides, it has also announced that Dr. Liu, Jun has been appointed as Chief Executive Officer of the Company and will cease to act as Chief Operating Officer and Vice General Manager.


Mr. Fu, Shan, Chairman of the Board of the Company, said, "To implement the strategic development plan of the Company in the next decade, the appointments of the Board and the management will be conducive to optimising the Company's management structure, or initiating a long-term succession plan for the management, so that the Company will achieve long-term sustainable development and be fully equipped to enter the commercialization development stage. Also, this move will enhance the development of the Company's overseas R&D projects and international cooperation projects, promoting its strategic deployment of internationalization."


Ms. Yeh-Huang has established a comprehensive industrial chain platform for the Company, laying major milestones as well as a solid foundation for its long-term development. She will also continue to promote the Company’s strategic development, enhancing its brand recognition and public relations.


As a scientist and senior management of the Company, Dr. Liu has been deeply involved in the R&D of biological drugs for years and also possesses profound experience in internationalization management. After taking the helm of CEO, the Board believes that Dr. Liu will continue to pursue the Company's strategic goal of developing TOT BIOPHARM into a leader in the field of China's antibody drug conjugate (“ADC”) and establish a competitive CDMO business platform, leading the Company to scale new heights.




Dr. Liu, Jun, aged 53, joined the Company as Deputy General Manager in October 2016, and was appointed as Executive Director, Chief Scientific Officer and Chief Operating Officer in October 2018, March 2019 and April 2020, respectively. He also serves as a member of the Strategic Committee, and is responsible for the Company’s R&D, supervising overall operations as well as business development.


Before joining the Company, Dr. Liu was the Senior Scientist of Bayer HealthCare's Global Biologics Development Group in Berkeley, the US, the Chief Researcher of Immunology Department at Beckman Research Institute in California, the US, and also the Executive Director of Biologics Research and Development Department at Shanghai ChemPartner Co., Ltd.


Dr. Liu possesses a professional background with international exposure, holding a PhD in Bioanalytical Chemistry from the University of California, Davis in the US and a Bachelor’s degree in Chemistry from the University of Science & Technology of China.


~ End ~


About TOT BIOPHARM International Company Limited (Stock Code: 1875.HK)

TOT BIOPHARM is dedicated to developing and commercializing innovative anti-tumour drugs and therapies, striving to build a leading brand of oncology treatments worthy of the trust of patients and their families, and medical professionals.


The Company has in place three major integrated technology platforms. They are:


Therapeutic Monoclonal Antibody and ADC Technology Platform: it integrates research and development (R&D) and production capacities for antibody-based drugs and ADC, with the designed production capacity of the commercialization base of biological drugs reaching 16,000L to accommodate high-quality commercialization of drug candidates;


Gene Engineering Based Therapeutics Technology Platform: it integrates anti-tumour immunotherapy, gene therapy and viral therapy and pursues R&D and production of tumour-targeted oncolytic virus products;


Innovative Drug Delivery Technology Platform: a comprehensive platform for the process development and commercial production of high intensity and frequency of drug injections. It adopts a production design with aseptic lyophilization and aseptic filling to satisfy the GMP production requirement of OEB 4/5 active level lyophilized powder and water needle.


Using these platforms, the Company has studied and developed various anti-tumour drug series and genres, and has formed a high quality and comprehensive drug product chain. On top of developing innovative proprietary drugs, the Company also draws on its own industry value chain to build a complete industry chain platform that supports operations from R&D and production and clinical development to marketing. By adopting an open platform business model, it is able to cooperate with biomedical enterprises and third parties at different stages along its industry value chain.